Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022003595 - METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE

Publication Number WO/2022/003595
Publication Date 06.01.2022
International Application No. PCT/IB2021/055870
International Filing Date 30.06.2021
IPC
A61K 31/7088 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
C12N 15/113 2010.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Applicants
  • JANSSEN BIOTECH, INC. [US]/[US]
Inventors
  • DEVINENI, Damayanthi
  • FREDERICK, Bart
  • SHU, Cathye
Agents
  • SHIRTZ, Joseph F.
  • XIA, Qing
Priority Data
63/047,16901.07.2020US
63/047,69502.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE
(FR) MÉTHODES D'ADMINISTRATION SÛRE D'UN OLIGONUCLÉOTIDE ANTISENS IRF5
Abstract
(EN) Methods of treating a human subject having a disease associated with Interferon Regulatory Factor 5 (IRF5) comprise administering to the subject an antisense oligomer to an IRF 5 nucleic acid.
(FR) Des méthodes de traitement d'un sujet humain ayant une maladie associée au facteur 5 de déclenchement de l'interféron (IRF5) comprennent l'administration au sujet d'un oligomère antisens à un acide nucléique IRF 5.
Latest bibliographic data on file with the International Bureau